GlassScriptPhysician profile
Sara E Crawford
NPI 1033758503
$2,180.84
in general payments reported to CMS, 2019-2025
20 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $362 · 2022: $431 · 2023: $752 · 2024: $500 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,387.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $403.43 | 2021-2024 | Olumiant, Taltz |
| Abbvie INC. | $358.76 | 2022-2024 | |
| Incyte Corporation | $298.94 | 2021-2024 | Opzelura |
| Genzyme Corporation | $176.31 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $146.23 | 2021-2024 | Libtayo, Dupixent |
| Janssen Biotech, INC. | $121.14 | 2022-2023 | Tremfya, Remicade, Stelara |
| Astrazeneca Pharmaceuticals LP | $119.76 | 2025 | Lynparza |
| Novartis Pharmaceuticals Corporation | $102.71 | 2021-2023 | |
| Amgen INC. | $65.11 | 2023 | Otezla |
| Dermavant Sciences, INC. | $52.49 | 2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $49.65 | 2023-2024 | Absorica Ld, Winlevi |
| Galderma Laboratories, L.P. | $44.94 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $43.17 | 2023 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $38.65 | 2023 | |
| Strata Skin Sciences, INC. | $35.75 | 2023 | Xtrac |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $29.31 | 2023 | |
| Ucb, INC. | $28.48 | 2022 | |
| Verrica Pharmaceuticals INC. | $26.14 | 2024 | Ycanth |
| Smith+Nephew, INC. | $22.93 | 2024 | Grafix Pl |
| Fresenius Kabi USA, LLC | $16.94 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.